SCHEMBL3019600

SCHEMBL3019600

COc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4c(C)cc(C)cc4C)CC3)n2)c(OC)c1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.43
ALDH1A1 P00352 3/20 0.43
RECQL P46063 2/20 0.43
USP2 O75604 2/20 0.42
HSD17B10 Q99714 1/20 0.42
KMT2A Q03164 3/20 0.40
POLB P06746 2/20 0.40
KDM4E B2RXH2 1/20 0.40
L3MBTL1 Q9Y468 3/20 0.39
LMNA P02545 2/20 0.39
HTT P42858 1/20 0.39
MAPK1 P28482 2/20 0.39
F2RL3 Q96RI0 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
TSHR P16473 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006221 0.93 MAPT (0.45) MAPTALDH1A1RECQLUSP2HSD17B10
SCHEMBL3022377 0.91 MAPT (0.43) MAPTALDH1A1RECQLUSP2HSD17B10
SCHEMBL2999461 0.89 MAPK1 (0.42) MAPTALDH1A1RECQLUSP2HSD17B10
SCHEMBL3012688 0.88 USP2 (0.51) MAPTALDH1A1RECQLUSP2HSD17B10
SCHEMBL3005922 0.88 MAPT (0.47) MAPTALDH1A1RECQLUSP2HSD17B10
SCHEMBL3013082 0.87 ALDH1A1 (0.46) MAPTALDH1A1RECQLUSP2HSD17B10
SCHEMBL3012685 0.87 KMT2A (0.45) MAPTALDH1A1RECQLUSP2HSD17B10
SCHEMBL3012037 0.87 MAPT (0.49) MAPTALDH1A1RECQLUSP2HSD17B10
SCHEMBL3014595 0.86 ALDH1A1 (0.55) MAPTALDH1A1RECQLUSP2HSD17B10
SCHEMBL3013946 0.86 MAPT (0.39) MAPTALDH1A1HSD17B10L3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885ALDH1A1 3510/4885RECQL 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.